BSE filing, NSE: LINCOLN. Summary written from the filing by ALFA Finder's alert engine.
Lincoln Pharmaceuticals Ltd: key numbers
- Share price
- ₹508.00
- Market cap
- ₹1,018 Cr
- Revenue (annual)
- ₹671.0 Cr
- Net profit (annual)
- ₹87.89 Cr
- P/E (TTM)
- 10.5×Sector 46.1×
- Promoter holding
- 49.78%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Lincoln Pharmaceuticals Ltd
All →Lincoln Pharmaceuticals Q2 FY27 Results: Net Profit ₹20.4 Cr, Up 2.0% YoY
Lincoln Pharmaceuticals Ltd reported revenue from operations of ₹191.3 Cr (+17.1% YoY) and net profit of ₹20.4 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹20.4 Cr · +2.0% YoY
Lincoln Pharmaceuticals Board Meeting Date
Lincoln Pharmaceuticals intimated that its Board meeting is scheduled for 29 Oct 2026 to approve Q1/H1 2026 financial results. Trading window remains closed until 48 hours after results are published.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals Ltd announced the resignation of Mr. Pradeep Kumar Yadav, Senior General Manager - Quality Assurance, effective October 17, 2026.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals submitted the minutes and voting results of its 32nd Annual General Meeting held on September 30, 2026. The meeting concluded successfully.
Lincoln Pharmaceuticals Annual General Meeting
Lincoln Pharmaceuticals held its 32nd Annual General Meeting on September 30, 2026, where shareholders considered financial statements, dividends, and director reappointments.
Lincoln Pharmaceuticals Management Change
Lincoln Pharmaceuticals announced the resignation of Mr. Manoj Rai, Sr. General Manager (Head QA), a Senior Management Personnel. He departs effective 24 September 2026 for personal reasons.
Other other announcement announcements
All →HEG Advanced Materials Other Announcement
HEG Advanced Materials Limited has intimated the exchange regarding the change of its Corporate Identification Number (CIN) following an approved scheme of arrangement.
Sanofi India Other Announcement
Sanofi India issued a communication regarding Tax Deduction at Source (TDS) for the interim dividend declared for FY 2026. Shareholders must update details by November 5, 2026.
Visaka Industries Other Announcement
Visaka Industries informed the exchange about sending reminder letters to shareholders regarding the compulsory transfer of unclaimed dividends and equity shares to the IEPF account.
Arvaya Healthcare Other Announcement
Arvaya Healthcare filed its quarterly shareholding pattern under Regulation 31(1)(c). The filing reports routine ownership breakdowns with no transaction.
AYM Syntex Other Announcement
AYM Syntex's board appointed BSR & Co. LLP as statutory auditor for five years, subject to shareholder approval. Routine auditor appointment; no monetary value involved.
- Execution
- Five consecutive years, from the conclusion of the 44th AGM to the conclusion of the 49th AGM
Kalpataru Other Announcement
Kalpataru filed CARE Ratings' IPO monitoring report for the quarter ended September 30, 2026. It reports no deviation from offer objects, though fund co-mingling was noted.